Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in the USA

Eur Respir J. 2018 Jul 27;52(1):1702106. doi: 10.1183/13993003.02106-2017. Print 2018 Jul.

Authors

Imre Noth¹, David Oelberg², Manika Kaul³, Craig S Conoscenti³, Ganesh Raghu⁴

Affiliations

¹ University of Virginia School of Medicine, Charlottesville, VA, USA.
² Western Connecticut Health Network, Danbury Hospital, Danbury, CT, USA.
³ Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
⁴ Dept of Medicine, University of Washington, Seattle, WA, USA.

PMID: 29794129
DOI: 10.1183/13993003.02106-2017

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Enzyme Inhibitors / adverse effects*
Enzyme Inhibitors / therapeutic use
Humans
Idiopathic Pulmonary Fibrosis / drug therapy*
Indoles / adverse effects*
Indoles / therapeutic use
Product Surveillance, Postmarketing
United States / epidemiology

Substances

Enzyme Inhibitors
Indoles
nintedanib

Grants and funding

R01 HL130796/HL/NHLBI NIH HHS/United States